BMP2 and neoplasm: TrkC blocks the BMP tumor suppressor activity through the suppression of bone morphogenetic protein 2 (BMP-2)-induced Smad1 phosphorylation and transcriptional activation by directly interacting with the BMP type II receptor [143].